Chief Executive Officer · ALNYLAM PHARMACEUTICALS, INC. (ALNY)

Yvonne Greenstreet

A named executive officer of ALNYLAM PHARMACEUTICALS in every fiscal year CompBrief holds from FY2023 to FY2025. Every figure below is printed as the company filed it and cited to the filing it came from.

Velarion Intel: free for 3 days, no card →

Total disclosed compensation, FY2025

$14,867,600

FY2024: $11,492,970

1st of 5 named executive officers at Alnylam Pharmaceuticals by FY2025 total.

5 named officers on file for ALNYLAM PHARMACEUTICALS, FY2025

See an example →

What this number hides

The filing gives the total. ALNYLAM PHARMACEUTICALS’s full Executive Compensation Report gives every award, the disclosed peer set and what the total leaves out — the pair adds the board’s.

Compensation figures as of the proxy filed April 6, 2026 (DEF 14A). Insider transactions since that proxy, current to 2026-11-06.

Free

Get Yvonne Greenstreet’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Also free: The Pay Desk, the weekly executive pay briefing.

Or track Yvonne Greenstreet and every company like it: Velarion Intel, free for 3 days, no card →

Yvonne Greenstreet compensation by year

ALNYLAM PHARMACEUTICALS Summary Compensation Table · all 3 fiscal years held
In US dollars, as ALNYLAM PHARMACEUTICALS reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2023FY2024FY2025
Salary$975,800$1,253,400$1,404,200
Bonus$0$0$0
Stock awards$3,375,150$3,625,000$5,512,500
Option awards$3,369,000$3,614,400$4,363,380
Non-equity incentive$1,155,000$2,975,400$3,562,500
Pension and deferred compensation$0$0$0
All other$20,720$24,770$25,020
Total$8,895,670$11,492,970$14,867,600

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: ALNYLAM PHARMACEUTICALS, INC. DEF 14A filed April 6, 2026, accession 0001628280-26-023923, and prior-year filings. Open the filing on EDGAR.

How this page was built: the ALNYLAM PHARMACEUTICALS, INC. filed document, accession 0001628280-26-023923. Every figure is read from that document and cited to the page and table it appears in. Filed April 6, 2026.

$8.9M
$11.5M
$14.9M
FY23
FY24
FY25
SalaryNon-equity incentiveStock awardsOption awardsAll other

Equity holdings

unvested awards at FY2025 year-end
TypeUnvested unitsValue at year-endExercise price
RSU71,860$28,575,129—
RSU24,867$9,888,363—
RSU19,003$7,556,543—
RSU17,965$7,143,782—
RSU15,836$6,297,185—
RSU5,921$2,354,486—
Option1,985—$147.47
Option11,493—$190.01
Option26,097—$152.61
Option36,293—$243.53

Per the Outstanding Equity Awards at Fiscal Year-End table in ALNYLAM PHARMACEUTICALS, INC.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.

Insider transactions since the last proxy

1 Form 4 line since the FY2025 proxy (filed April 6, 2026)
current to 2026-11-06 · updated nightly
DateTransactionPlanSharesPriceHeld after
2026-09-19Grant or award—107$0.0095,802

The 1 most recent of 1 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →

ALNYLAM PHARMACEUTICALS’s named executive officers, FY2025

as the company reported each
Named executive officerRoleFY2025 total
Yvonne Greenstreet · this pageChief Executive Officer$14,867,600
Jeffrey PoultonExecutive Vice President, Chief Financial Officer$6,863,800
Bryan SupranExecutive Vice President, Chief Legal Officer and Secretary$6,846,350
Pushkal GargExecutive Vice President, Chief Research and Development Officer$6,490,500
Tolga TangulerExecutive Vice President, Chief Commercial Officer$6,129,020

Board service

ALNYLAM PHARMACEUTICALS board · FY2022–FY2025

How this board is paid

Company policy: ALNYLAM PHARMACEUTICALS pays directors a $60,000 cash retainer and $400,000 in 50% Stock Options, 50% RSUs. As stated in ALNYLAM PHARMACEUTICALS's FY2025 proxy.

The full ALNYLAM PHARMACEUTICALS compensation record

free company brief

This page is one person within ALNYLAM PHARMACEUTICALS's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the ALNYLAM PHARMACEUTICALS proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order ALNYLAM PHARMACEUTICALS's full Executive Compensation Report with peer benchmarking.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are ALNYLAM PHARMACEUTICALS's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Order ALNY

Add the email the receipt and the PDF go to, then press the report you want. Each button opens its own card payment on Stripe.

Receipt, invoice, and report delivery. Guest checkout, no account required, secure payment by Stripe.

Yvonne Greenstreet's compensation dossier